MassDevice Q&A: Jean-Marc Wismer

July 14, 2009 by Brian Johnson

The CEO of Switzerland's Sensimed looks to peel back the lid on glaucoma testing.

You literally cannot see glaucoma coming.

Although it's one of the leading causes of blindness in the world, frighteningly little is known about a disease group that affects 4 percent of the world's population over the age of 40. No cure is on the horizon. And due to the insidious nature of the disease, which stars gradually affecting sight from the periphery, most people don't even know they're suffering from glaucoma until it's too late.

Swiss diagnostics company Sensimed AG sees this mysterious disease as a real opportunity.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Haemonetics CEO Brian Concannon discusses how the company will transform blood management in the coming years at MassDevice.com's DeviceTalks Boston event.

Calhoun Vision CEO Verne Sharma tells MassDevice.com why his company's light-adjustable lens will disrupt the practice of ophthalmology.

Kevin King, CEO of Silicon Valley digital health company iRhythm, tells MassDevice about the promise of Big Data and how remote patient monitoring can reveal intricate details of the habits of the heart.

Covidien's Stacy Enxing Seng speaks to MassDevice.com about the Medtronic merger during our DeviceTalks Minnesota event.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp